Centessa Pharmaceuticals plc - ADR Forecast, price target & analysts
Centessa Pharmaceuticals plc - ADR Target price 2025 - Analyst rating & recommendation
Centessa Pharmaceuticals plc - ADR Classifications & Recommendation:
Centessa Pharmaceuticals plc - ADR Price Target
| Target Price | $31.56 |
| Price | $13.20 |
| Potential |
139.06%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Centessa Pharmaceuticals plc - ADR 2026 .
The average Centessa Pharmaceuticals plc - ADR target price is $31.56.
This is
139.06%
register free of charge
$38.00
187.88%
register free of charge
$27.00
104.55%
register free of charge
|
|
| A rating was issued by 10 analysts: 10 Analysts recommend Centessa Pharmaceuticals plc - ADR to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Centessa Pharmaceuticals plc - ADR stock has an average upside potential 2026 of
139.06%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.00 | 13.50 |
| 100.00% |
10 Analysts have issued a sales forecast Centessa Pharmaceuticals plc - ADR 2025 . The average Centessa Pharmaceuticals plc - ADR sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Centessa Pharmaceuticals plc - ADR EBITDA forecast 2025. The average Centessa Pharmaceuticals plc - ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Margin
5 Centessa Pharmaceuticals plc - ADR Analysts have issued a net profit forecast 2025. The average Centessa Pharmaceuticals plc - ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Margin
| 2029 |
12.70%
107.66%
Unlock
|
|
|---|---|---|
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.06 | -1.32 |
| 31.21% | 35.92% | |
| P/E | negative | |
| EV/Sales | 118.25 |
5 Analysts have issued a Centessa Pharmaceuticals plc - ADR forecast for earnings per share. The average Centessa Pharmaceuticals plc - ADR EPS is
This results in the following potential growth metrics and future valuations:
Centessa Pharmaceuticals plc - ADR...
Current Centessa Pharmaceuticals plc - ADR Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Chardan Capital |
Locked
➜
Locked
|
Locked | May 08 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Mar 26 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Feb 10 2025 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Jan 07 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Nov 15 2024 |
| B. Riley Securities |
Locked
➜
Locked
|
Locked | Sep 19 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Chardan Capital:
Locked
➜
Locked
|
May 08 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Mar 31 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Mar 26 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Feb 10 2025 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Jan 07 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Nov 15 2024 |
|
Locked
B. Riley Securities:
Locked
➜
Locked
|
Sep 19 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
